Start / Cell & Gene: The Podcast / Pepgens svp head of clinical development on delivery of oligonucleotide therapies

PepGen's SVP Head Of Clinical Development On Delivery Of Oligonucleotide Therapies

31 min • 27 oktober 2022

We love to hear from our listeners. Send us a message.

PepGen, a Cambridge, MA-based biotech, is advancing oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases has focused on delivery. SVP Head of Clinical Development Dr. Michelle Mellion explains PepGen's trial of PGN-EDO51, the company’s lead product candidate for the treatment of DMD patients whose mutations are amenable to an exon 51 skipping approach. She also explains how the delivery of oligonucleotide therapies differ from other techniques in genetic medicine, and much more.

Subscribe to the podcast!
Apple | Spotify | YouTube

Senaste avsnitt

Rethinking Large Animal Models in Gene Therapy with Novartis' Ralf Schmid, Ph.D.

17 juli | 25 min

Gene Therapy for Inherited Retinal Diseases with Opus Genetics' Dr. George Magrath

3 juli | 20 min

Extracellular Vesicle Breakthroughs with Aegle Therapeutics' Dr. Gloria Matthews

19 juni | 16 min

Bridging Development and Regulation in CGT with Halloran Consulting Group's Monika Swietlicka

5 juni | 25 min

Harnessing AI and Synthetic Biology for Cell Therapies with Generate:Biomedicines' Dr. Alex Snyder

22 maj | 19 min

Redefining Heart Failure Treatment with Precision Autologous Cell Therapy with BioCardia's Peter Altman, Ph.D.

8 maj | 18 min

CGT Manufacturing: Distributed & Digital with Deloitte Consulting's Omkar Kawalekar, Ph.D.

27 februari | 29 min

Inside Gene Therapies for Cardiac Care with Tenaya Therapeutics' Faraz Ali

13 februari | 36 min

The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

30 januari | 27 min

The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan

16 januari | 24 min

Lessons in Automation with Roswell Park Comprehensive Cancer Center's Christopher Choi, Ph.D.

2 januari | 15 min

Can Gene Therapy Be the Solution for CHF with AskBio's Dr. Lothar Roessig

19 december 2024 | 21 min

Inside a Dopamine-Restoring Cell Therapy for PD with BlueRock Therapeutics' Dr. Amit Rahkit

5 december 2024 | 31 min

Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene

21 november 2024 | 22 min

Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

7 november 2024 | 21 min

Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte

24 oktober 2024 | 25 min

Pioneering Next-Gen TCR Therapies in Solid Tumors with Neogene Therapeutics’ Carsten Linnemann, Ph.D.

10 oktober 2024 | 14 min

Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge

25 september 2024 | 22 min

A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino

12 september 2024 | 28 min

Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

29 augusti 2024 | 25 min

CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D.

15 augusti 2024 | 28 min

Identifying Drug Development Opportunities for DMD with CureDuchenne

1 augusti 2024 | 30 min

Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington

18 juli 2024 | 21 min

TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

4 juli 2024 | 36 min

Synthetic Biology and Programmable mRNA with Strand Therapeutics' Jake Becraft

20 juni 2024 | 28 min

Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko

6 juni 2024 | 15 min

The Current State of the Global Regulatory Landscape with ISCT's Dr. Bambi Grilley

28 maj 2024 | 25 min

Dr. Bruce Levine on ISCT and the Future of CAR-T

23 maj 2024 | 32 min

CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant

9 maj 2024 | 19 min

Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah

25 april 2024 | 30 min

Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang

11 april 2024 | 23 min

Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan

28 mars 2024 | 20 min

Inside Cellular Rejuvenation Therapies for Age-Related Diseases with Life Biosciences' Sharon Rosenzweig-Lipson, Ph.D.

14 mars 2024 | 17 min

The Future of Rare Diseases with The Jackson Laboratory’s Rare Disease Translational Center's Cat Lutz

29 februari 2024 | 28 min

Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald

15 februari 2024 | 21 min

Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng.

1 februari 2024 | 37 min

Breaking Down Solid Tumors with Triumvira Immunologics' Dr. Paul Lammers

18 januari 2024 | 22 min

4 Keys to Allo in 2024 with Poseida Therapeutics' Kristin Yarema, Ph.D.

4 januari 2024 | 32 min

Cell Therapy For Corneal Endothelial Dystrophies With Aurion Biotech's Greg Kunst

21 december 2023 | 14 min

Overcoming the Limitations of CAR T-Cell Therapy with Vittoria Bio's Nick Siciliano, Ph.D.

7 december 2023 | 17 min

Gene Therapy Deals, Collaborations, & Partnerships with Astellas' Richard Wilson

21 november 2023 | 25 min

The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills

9 november 2023 | 29 min

Inside 2023 Meeting on the Mesa with ARM's COO, Rita Johnson-Greene

26 oktober 2023 | 17 min

The Future of Cell and Organ Transplantation in Treating T1D with Dr. Camillo Ricordi

12 oktober 2023 | 18 min

In Vivo CAR T-Cell Therapeutics With Umoja Biopharma's Dr. Andrew Scharenberg

28 september 2023 | 31 min

Inside Genome Editing with CBER's Dr. Peter Marks

14 september 2023 | 25 min

The Future of CAR-T with Bristol Myers Squibb's Lynelle Hoch

31 augusti 2023 | 26 min

The Promise of Genome Editing with Caribou Biosciences' Rachel Haurwitz, Ph.D.

17 augusti 2023 | 23 min

Focus Areas For Cell Therapy With Bristol Myers Squibb's Stephan Krause, Ph.D.

3 augusti 2023 | 19 min

The Intersection Of RNA, AI, And Synthetic Biology With Shape Therapeutics' Dr. Francois Vigneault

20 juli 2023 | 29 min

Inside Prime Editing with Prime Medicine's Dr. Andrew Anzalone

6 juli 2023 | 25 min

Navigating CMC Challenges with Parenteral Drug Association's Glenn Wright

22 juni 2023 | 25 min

An Interview with Dr. Usman "Oz" Azam

8 juni 2023 | 28 min

Targeting Oncogenic Drivers for Solid Tumor Cancers with Affini-T Therapeutics' Dr. Jak Knowles

25 maj 2023 | 24 min

TJU's Jefferson Institute for Bioprocessing's Impact on CGT with Parviz Shamlou

11 maj 2023 | 42 min

Computational Biology's Role In Gene Therapy With Kriya Therapeutics' Dr. Shankar Ramaswamy

27 april 2023 | 32 min

The Near-Term Future of Exosome Science with Capricor Therapeutics' Dr. Linda Marbán

13 april 2023 | 28 min

Inside the World's First-Ever Allogeneic Approval with Atara Biotherapeutics' Pascal Touchon

30 mars 2023 | 41 min

The Potential of RNA Exon Editing with Ascidian Therapeutics' Romesh Subramanian, Ph.D.

16 mars 2023 | 21 min

Automating Processes to Scale CGT Manufacturing with PA Consulting's Paolo Siciliano

2 mars 2023 | 32 min

The Why Behind In-House Manufacturing With Sangamo's Andy Ramelmeier

16 februari 2023 | 22 min

2023 Market Outlook with AdBio and ISCT's Miguel Forte

2 februari 2023 | 27 min

CMC and Scale Up with Mustang Bio's Robert Sexton

19 januari 2023 | 36 min

An Interview with Dr. Peter Marks

5 januari 2023 | 29 min

Inside NK and Macrophage Cellular Immunotherapies with Shoreline Biosciences CSO Dr. Robert Hollingsworth

22 december 2022 | 27 min

The Future of iPSCs with BlueRock Therapeutics' CEO Seth Ettenberg

8 december 2022 | 29 min

Manufacturing at the Point of Care with Orgenesis' CEO Vered Caplan

24 november 2022 | 37 min

Capstan Therapeutics' CEO Laura Shawver on In Vivo Cell Engineering

10 november 2022 | 40 min